Department of Experimental Pediatrics, University Hospital, Health Campus Immunology, Infectiology and Inflammation, Otto-von-Guericke-University Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, Germany.
Department of Experimental Pediatrics, University Hospital, Health Campus Immunology, Infectiology and Inflammation, Otto-von-Guericke-University Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, Germany.
Semin Immunol. 2019 Apr;42:101298. doi: 10.1016/j.smim.2019.101298.
Coreceptor-based immunotherapy is a rapidly developing approach to treat cancer patients. Among those targeted receptors, CTLA-4 is the primary attenuator of adaptive immune responses and the most prominent and extensively investigated molecule in this field. CTLA-4 is involved in broad range of mechanisms that regulate and control immune cell functions and therefore provides versatile strategies for therapeutic interventions. Despite being successfully harnessed in clinical treatments the different facets of CTLA-4 biology still remain incompletely understood. Here, we review the various aspects of CTLA-4 functions and CTLA-4-based immunotherapies and discuss challenges to improve current approaches.
基于共受体的免疫疗法是一种治疗癌症患者的快速发展的方法。在这些靶向受体中，CTLA-4 是适应性免疫反应的主要衰减器，也是该领域中最突出和广泛研究的分子。CTLA-4 参与广泛的机制，调节和控制免疫细胞的功能，因此为治疗干预提供了多种策略。尽管在临床治疗中已成功利用 CTLA-4，但 CTLA-4 生物学的不同方面仍不完全了解。在这里，我们综述了 CTLA-4 功能和 CTLA-4 为基础的免疫疗法的各个方面，并讨论了改善当前方法的挑战。
